These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7851496)

  • 1. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment.
    Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
    Eur J Pharmacol; 1994 Oct; 269(2):201-8. PubMed ID: 7851496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine.
    Kuoppamäki M; Pälvimäki EP; Syvälahti E; Hietala J
    Eur J Pharmacol; 1994 Apr; 255(1-3):91-7. PubMed ID: 8026557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol.
    Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1262-7. PubMed ID: 8383744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
    Syvälahti E; Penttilä J; Majasuo H; Pälvimäki EP; Laakso A; Hietala J
    Pharmacopsychiatry; 2006 Jan; 39(1):1-8. PubMed ID: 16453246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.
    Hietala J; Kuonnamäki M; Pälvimäki EP; Laakso A; Majasuo H; Syvälahti E
    Psychopharmacology (Berl); 2001 Sep; 157(2):180-7. PubMed ID: 11594443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic citalopram and fluoxetine treatments upregulate 5-HT2c receptors in the rat choroid plexus.
    Laakso A; Pälvimäki EP; Kuoppamäki M; Syvälahti E; Hietala J
    Neuropsychopharmacology; 1996 Aug; 15(2):143-51. PubMed ID: 8840350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs.
    Kuoppamäki M; Pälvimäki EP; Hietala J; Syvälahti E
    Neuropsychopharmacology; 1995 Oct; 13(2):139-50. PubMed ID: 8597525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation.
    Pälvimäki EP; Majasuo H; Kuoppamäki M; Männistö PT; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1998 Mar; 136(2):99-104. PubMed ID: 9551765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of 5-HT1C receptors and phosphoinositide system by ethanol consumption in rat brain and choroid plexus.
    Pandey SC; Dubey MP; Piano MR; Schwertz DW; Davis JM; Pandey GN
    Eur J Pharmacol; 1993 Sep; 247(1):81-8. PubMed ID: 8258364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments.
    Pälvimäki EP; Majasuo H; Syvälahti E; Hietala J
    Pharmacol Res; 2005 May; 51(5):419-25. PubMed ID: 15749456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics.
    Canton H; Verrièle L; Millan MJ
    Neurosci Lett; 1994 Nov; 181(1-2):65-8. PubMed ID: 7898773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
    Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
    J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
    Wilmot CA; Szczepanik AM
    Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.
    Kuoppamäki M; Syvälahti E; Hietala J
    Eur J Pharmacol; 1993 Apr; 245(2):179-82. PubMed ID: 8387927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
    Smith RL; Canton H; Barrett RJ; Sanders-Bush E
    Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat.
    Zhao C; Li M
    Neuroscience; 2010 Apr; 166(4):1043-55. PubMed ID: 20096751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The receptor mechanisms underlying the disruptive effects of haloperidol and clozapine on rat maternal behavior: a double dissociation between dopamine D(2) and 5-HT(2A/2C) receptors.
    Zhao C; Li M
    Pharmacol Biochem Behav; 2009 Oct; 93(4):433-42. PubMed ID: 19539643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis.
    Wolf WA; Schutz LJ
    J Neurochem; 1997 Oct; 69(4):1449-58. PubMed ID: 9326273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin agonists increase transferrin levels via activation of 5-HT1C receptors in choroid plexus epithelium.
    Esterle TM; Sanders-Bush E
    J Neurosci; 1992 Dec; 12(12):4775-82. PubMed ID: 1334504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.